Biocryst Pharmaceuticals Inc (BCRX)

07:17 AM

BioCryst to Report First Quarter 2025 Financial Results on May 5 | BCRX Stock News - GuruFocus

07:17 AM

07:14 AM

BioCryst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 5, 2025 - Nasdaq

07:14 AM

07:02 AM

BioCryst to Report First Quarter 2025 Financial Results on May 5 - GlobeNewswire

07:02 AM

07:00 AM

BioCryst Earnings Preview: Key Financial Updates and Corporate Strategy Reveal Coming May 5 - Stock Titan

07:00 AM

Apr 20, 2025

Where are the Opportunities in (BCRX) - news.stocktradersdaily.com

Apr 20, 2025

Apr 17, 2025

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st

Apr 17, 2025

Apr 11, 2025

BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus

Apr 11, 2025

Apr 10, 2025

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry - TradingView

Apr 10, 2025

Apr 10, 2025

BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO - MSN

Apr 10, 2025

Apr 10, 2025

BioCryst appoints interim CFO following executive departure By Investing.com - Investing.com India

Apr 10, 2025

Apr 10, 2025

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis - MarketScreener

Apr 10, 2025

Apr 10, 2025

Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting OfficerSEC Filing - marketscreener.com

Apr 10, 2025

Apr 10, 2025

BioCryst Appoints CEO as Interim CFO Amid Transition - TipRanks

Apr 10, 2025

Apr 10, 2025

BioCryst appoints interim CFO following executive departure - Investing.com

Apr 10, 2025

Apr 09, 2025

BioCryst at Needham Conference: Growth Amidst Competition By Investing.com - Investing.com India

Apr 09, 2025

Apr 09, 2025

BioCryst at Needham Conference: Growth Amidst Competition - Investing.com

Apr 09, 2025

Apr 04, 2025

(BCRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 04, 2025

Apr 04, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 04, 2025

Apr 04, 2025

BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan

Apr 04, 2025

Apr 03, 2025

BioCryst to Present at Upcoming Investor Conference - The Manila Times

Apr 03, 2025

Apr 02, 2025

BioCryst Takes Center Stage: Key Updates Coming at Major Healthcare Conference - Stock Titan

Apr 02, 2025

Apr 02, 2025

Plasma Protease C1-inhibitor Market Size, Growth Report 2034 - Global Market Insights Inc.

Apr 02, 2025

Apr 01, 2025

Biocryst discovers new KLK5 inhibitors - BioWorld MedTech

Apr 01, 2025

Mar 27, 2025

BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews

Mar 27, 2025

Mar 19, 2025

North Carolina biotech sues to block copies of $400M drug - The Business Journals

Mar 19, 2025

Mar 18, 2025

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance

Mar 18, 2025

Mar 18, 2025

Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego

Mar 18, 2025

Mar 18, 2025

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St

Mar 18, 2025

Mar 14, 2025

(BCRX) Technical Data - news.stocktradersdaily.com

Mar 14, 2025

Mar 14, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 14, 2025

Mar 13, 2025

25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World

Mar 13, 2025

Mar 13, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com

Mar 12, 2025

Mar 11, 2025

BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Mar 11, 2025

Mar 11, 2025

BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada

Mar 11, 2025

Mar 11, 2025

BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law News

Mar 11, 2025

Mar 11, 2025

BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView

Mar 11, 2025

Mar 11, 2025

BioCryst sues to protect ORLADEYO patents - Investing.com India

Mar 11, 2025

Mar 11, 2025

Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com

Mar 11, 2025

Mar 09, 2025

Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com

Mar 09, 2025

Mar 09, 2025

Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Mar 09, 2025

Mar 06, 2025

Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News

Mar 06, 2025

Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com

Mar 06, 2025

Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK

Mar 06, 2025

Mar 06, 2025

BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com

Mar 06, 2025

Mar 06, 2025

BioCryst reports inducement grants under Nasdaq listing rule - TipRanks

Mar 06, 2025

Mar 06, 2025

BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan

Mar 06, 2025

Mar 06, 2025

BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia

Mar 06, 2025

Mar 05, 2025

CFO Anthony Doyle resigns at Biocryst - biocentury.com

Mar 05, 2025